Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Reports Strong Q2 2024 Financial Results and Updates Guidance
Summary
Jazz Pharmaceuticals plc reported strong financial results for the second quarter of 2024, with total revenues of $1.02 billion, representing a 7% increase year-over-year. The company announced a 15% year-over-year increase in revenue from its key growth drivers: Xywav, Epidiolex, and Rylaze. Oncology revenues grew by 10% year-over-year. Jazz Pharmaceuticals updated its full-year 2024 financial guidance, narrowing its total revenue range to $4.0 to $4.1 billion and affirming its GAAP and non-GAAP adjusted net income guidance. The company also announced a new $500 million share repurchase program.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement